Federal Register of Legislation - Australian Government

Primary content

PB 74 of 2022 Determinations/Health as made
This instrument amends the National Health (Price and Special Patient Contribution) Determination 2021 by increasing and imposing claimed prices and brand premiums for multiple brands of specified pharmaceutical items.
Administered by: Health and Aged Care
Registered 29 Jul 2022
Tabling HistoryDate
Tabled HR01-Aug-2022
Tabled Senate02-Aug-2022
To be repealed 23 Nov 2022
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB  74 of 2022

 

National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 6)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated           28  July 2022                   

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

 

 


Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments                                                                                           2

National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021) 2

 

 


1  Name

                   This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 6).

                   This instrument may also be cited as PB 74 of 2022.

2  Commencement

             (1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 August 2022

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under section 85B of the National Health Act 1953.

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1Amendments

National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021)

1.    Schedule 1, entry for Ezetimibe

 

Omit

Ezetimibe

Tablet 10 mg

Oral

Ezetrol

30

8.28

11.01

 

 

            Insert

Ezetimibe

Tablet 10 mg

Oral

Ezetrol

30

8.28

11.44

 

2.    Schedule 1, entry for Ezetimibe and rosuvastatin

Omit

Ezetimibe and rosuvastatin

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)

Oral

Rosuzet Composite Pack

1

9.39

12.69

 

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)

Oral

Rosuzet Composite Pack

1

10.83

14.17

 

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)

Oral

Rosuzet Composite Pack

1

10.59

13.94

 

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)

Oral

Rosuzet Composite Pack

1

11.57

14.96

 

 

Substitute

Ezetimibe and rosuvastatin

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)

Oral

Rosuzet Composite Pack

1

9.39

13.11

 

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)

Oral

Rosuzet Composite Pack

1

10.83

14.55

 

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)

Oral

Rosuzet Composite Pack

1

10.59

14.31

 

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)

Oral

Rosuzet Composite Pack

1

11.57

15.29

3.    Schedule 1, after entry for Ezetimibe and rosuvastatin

 

Insert

Ezetimibe with atorvastatin

Tablet 10 mg-10 mg

Oral

Atozet

30

9.70

12.49

 

Tablet 10 mg-20 mg

Oral

Atozet

30

10.38

13.17

 

Tablet 10 mg-40 mg

Oral

Atozet

30

11.23

14.02

 

Tablet 10 mg-80 mg

Oral

Atozet

30

12.50

15.29

 

4.    Schedule 1, entry for Metformin

 

             Omit

Metformin

Tablet containing metformin hydrochloride 500 mg

Oral

Diabex

100

2.50

7.11

 

Tablet (extended release) containing metformin hydrochloride 500 mg

Oral

Diabex XR 500

120

4.01

8.61

 

Tablet containing metformin hydrochloride 850 mg

Oral

Diabex 850

60

2.50

7.11

 

Tablet containing metformin hydrochloride 1 g

Oral

Diabex 1000

90

4.36

8.97

 

Tablet (extended release) containing metformin hydrochloride 1 g

Oral

Diabex XR 1000

60

4.01

8.61

 

Substitute

Metformin

Tablet containing metformin hydrochloride 500 mg

Oral

Diabex

100

2.50

7.59

 

Tablet (extended release) containing metformin hydrochloride 500 mg

Oral

Diabex XR 500

120

4.01

8.99

 

Tablet containing metformin hydrochloride 850 mg

Oral

Diabex 850

60

2.50

7.59

 

Tablet containing metformin hydrochloride 1 g

Oral

Diabex 1000

90

4.36

9.32

 

Tablet (extended release) containing metformin hydrochloride 1 g

Oral

Diabex XR 1000

60

4.01

8.99

 

5.    Schedule 1, entry for Telmisartan

 

           Omit

Telmisartan

Tablet 40 mg

Oral

Micardis

28

1.65

5.83

 

Tablet 80 mg

Oral

Micardis

28

4.78

8.97

 

         Insert

Telmisartan

Tablet 40 mg

Oral

Micardis

28

1.65

6.86

 

Tablet 80 mg

Oral

Micardis

28

4.78

9.76

 

6.    Schedule 1, entry for Telmisartan with amlodipine

 

             Omit

Telmisartan with amlodipine

Tablet 40 mg‑5 mg (as besilate)

Oral

Twynsta

28

2.42

6.60

 

Tablet 40 mg‑10 mg (as besilate)

Oral

Twynsta

28

3.02

7.21

 

Tablet 80 mg‑5 mg (as besilate)

Oral

Twynsta

28

5.55

9.74

 

Tablet 80 mg‑10 mg (as besilate)

Oral

Twynsta

28

6.15

10.33

 

 

 

 

 

 

 

 

Substitute

Telmisartan with amlodipine

Tablet 40 mg‑5 mg (as besilate)

Oral

Twynsta

28

2.42

7.56

 

Tablet 40 mg‑10 mg (as besilate)

Oral

Twynsta

28

3.02

8.12

 

Tablet 80 mg‑5 mg (as besilate)

Oral

Twynsta

28

5.55

10.48

 

Tablet 80 mg‑10 mg (as besilate)

Oral

Twynsta

28

6.15

11.08

 

 

 

 

 

 

 

 

7.    Schedule 1, entry for Telmisartan with hydrochlorothiazide

 

 Omit

Telmisartan with hydrochlorothiazide

Tablet 40 mg‑12.5 mg

Oral

Micardis Plus 40/12.5 mg

28

2.12

6.31

 

Tablet 80 mg‑12.5 mg

Oral

Micardis Plus 80/12.5 mg

28

5.29

9.48

 

Tablet 80 mg‑25 mg

Oral

Micardis Plus 80/25 mg

28

5.76

9.94

 

Substitute

Telmisartan with hydrochlorothiazide

Tablet 40 mg‑12.5 mg

Oral

Micardis Plus 40/12.5 mg

28

2.12

7.28

 

Tablet 80 mg‑12.5 mg

Oral

Micardis Plus 80/12.5 mg

28

5.29

10.23

 

Tablet 80 mg‑25 mg

Oral

Micardis Plus 80/25 mg

28

5.76

10.69